Novo Nordisk, the world’s largest insulin producer, and LifeScan, Inc., the leading maker of blood glucose monitoring systems, have announced a worldwide alliance to enhance diabetes management solutions.
Under the agreement, the companies will work together to bring two complimentary product lines to people with diabetes-Novo Nordisk’s insulin products and future oral hypoglycemic agents, and LifeScan’s blood glucose meters. The details of the union will be determined on a country-by-country basis.
“By jointly marketing with Novo Nordisk,” says LifeScan president Richard Wiesner, “we will be able to benefit from each other’s strengths in providing people with diabetes and health professionals with simple, accessible solutions to their diabetes management needs.”
LifeScan, an American company, brings extensive knowledge of the U.S. blood glucose monitoring market to the partnership. Novo Nordisk’s experience in other countries, especially Europe and Japan, will help LifeScan globalize its activities. The alliance will offer people a complete diabetes management option that stresses the combination of therapeutics and glucose monitors, as well as educational material, therapeutic guidelines, and compliance programs.
Says Mads Ovlisen, president and CEO of Novo Nordisk, “With the application of optimal treatment guidelines, which include the availability and correct use of drugs and blood glucose monitoring systems, quality of care will increase and costs decrease.”